|
1
|
Sørlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cetin I and Topcul M: Triple negative
breast cancer. Asian Pac J Cancer Prev. 15:2427–2431. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rouleau M, Patel A, Hendzel MJ, Kaufmann
SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev
Cancer. 10:293–301. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weil MK and Chen AP: PARP inhibitor
treatment in ovarian and breast cancer. Curr Probl Cancer. 35:7–50.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ibrahim NK, Desai N, Legha S, Soon-Shiong
P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A,
Hortobagyi GN, et al: Phase I and pharmacokinetic study of ABI-007,
a Cremophor-free, protein-stabilized, nanoparticle formulation of
paclitaxel. Clin Cancer Res. 8:1038–1044. 2002.PubMed/NCBI
|
|
7
|
ten Tije AJ, Verweij J, Loos WJ and
Sparreboom A: Pharmacological effects of formulation vehicles:
Implications for cancer chemotherapy. Clin Pharmacokinet.
42:665–685. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gradishar WJ, Tjulandin S, Davidson N,
Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III
trial of nanoparticle albumin-bound paclitaxel compared with
polyethylated castor oil-based paclitaxel in women with breast
cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reis-Filho JS and Tutt ANJ: Triple
negative tumours: A critical review. Histopathology. 52:108–118.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saha P and Nanda R: Concepts and targets
in triple-negative breast cancer: Recent results and clinical
implications. Ther Adv Med Oncol. 8:351–359. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Topcul M and Cetin I: Endpoint of cancer
treatment: Targeted therapies. Asian Pac J Cancer Prev.
15:4395–4403. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rouzier R, Perou CM, Symmans WF, Ibrahim
N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P,
et al: Breast cancer molecular subtypes respond differently to
preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Shaughnessy J, Yoffe M, Osborne C, Blum
J, Rocha C, Ossovskaya V, Sherman B and Bradley C: Triple negative
breast cancer: A phase 2, multi-center, open-label, randomized
trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a
PARP inhibitor. Cancer Res. 69 Suppl:21202009. View Article : Google Scholar
|
|
15
|
Dent RA, Lindeman GJ, Clemons M, Wildiers
H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL and
Carmichael J: Phase I trial of the oral PARP inhibitor olaparib in
combination with paclitaxel for first- or second-line treatment of
patients with metastatic triple-negative breast cancer. Breast
Cancer Res. 15:R882013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Graziani G and Szabó C: Clinical
perspectives of PARP inhibitors. Pharmacol Res. 52:109–118. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hastak K, Alli E and Ford JM: Synergistic
chemosensitivity of triple-negative breast cancer cell lines to
poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.
Cancer Res. 70:7970–7980. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jacob DA, Bahra M, Langrehr JM, Boas-Knoop
S, Stefaniak R, Davis J, Schumacher G, Lippert S and Neumann UP:
Combination therapy of poly (ADP-ribose) polymerase inhibitor
3-aminobenzamide and gemcitabine shows strong antitumor activity in
pancreatic cancer cells. J Gastroenterol Hepatol. 22:738–748.
2007.PubMed/NCBI
|
|
19
|
Schiff PB and Horwitz SB: Taxol stabilizes
microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA.
77:1561–1565. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jordan MA and Wilson L: Microtubules and
actin filaments: Dynamic targets for cancer chemotherapy. Curr Opin
Cell Biol. 10:123–130. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jordan MA, Toso RJ, Thrower D and Wilson
L: Mechanism of mitotic block and inhibition of cell proliferation
by taxol at low concentrations. Proc Natl Acad Sci USA.
90:9552–9556. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Crown J and O'Leary M: The taxanes: An
update. Lancet. 355:1176–1178. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kratz F: Albumin as a drug carrier: Design
of prodrugs, drug conjugates and nanoparticles. J Control Release.
132:171–183. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Untch M, Jackisch C, Schneeweiss A, Conrad
B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S,
Hilfrich J, et al: German Breast Group (GBG); Arbeitsgemeinschaft
Gynäkologische Onkologie-Breast (AGO-B) Investigators:
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant
chemotherapy for early breast cancer (GeparSepto-GBG 69): A
randomised, phase 3 trial. Lancet Oncol. 17:345–356. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Giaccone G, Rajan A, Kelly RJ, Gutierrez
M, Kummar S, Yancey M, Ji JJ, Zhang Y, Parchment RE and Doroshow
JH: A phase I combination study of olaparib (AZD2281; KU-0059436)
and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.
J Clin Oncol. 28 suppl 15:30272010. View Article : Google Scholar
|
|
26
|
Haince JF, Kozlov S, Dawson VL, Dawson TM,
Hendzel MJ, Lavin MF and Poirier GG: Ataxia telangiectasia mutated
(ATM) signaling network is modulated by a novel
poly(ADP-ribose)-dependent pathway in the early response to
DNA-damaging agents. J Biol Chem. 282:16441–16453. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang B, Guo RF, Tan XH, Zhao M, Tang ZB
and Lu YY: Expression status of ataxia-telangiectasia-mutated gene
correlated with prognosis in advanced gastric cancer. Mutat Res.
638:17–25. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cetin I and Topcul MR: In vitro
antiproliferative effects of nab-paclitaxel with liposomal
cisplatin on MDA-MB-231 and MCF-7 breast cancer cell lines. J BUON.
22:347–354. 2017.PubMed/NCBI
|
